On Friday, shares of telemedicine platform Mangoceuticals (MGRX.US) dropped nearly 13% in pre-market trading before recovering slightly to a 2.94% gain at market open, trading at $1.225. The company retracted its previous day's announcement, denying any partnership with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US).
During Thursday's pre-market session, Mangoceuticals had claimed collaborations with Eli Lilly and Novo Nordisk, stating it would provide GLP-1 weight-loss drugs from these pharmaceutical giants through its MangoRx Direct and PeachesRx Direct programs. However, the situation took a sharp turn when Eli Lilly publicly refuted the partnership, and Novo Nordisk also failed to confirm the claims.